Stockscreener 앱 받기
113.91
0.28%
-0.32
시간 외 거래:
113.91
Palvella Therapeutics Inc 주식(PVLA)의 최신 뉴스
Topical statins show promise for rare skin disease in new review - MSN
Clear Street initiates coverage of Palvella Therapeutics (PVLA) with buy recommendation - MSN
Fred Alger Management LLC Increases Stock Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella receives European patent for rapamycin gel formulation By Investing.com - Investing.com India
Palvella Therapeutics: A Potential First-In-Class Therapy In A Rare Dermatology Market - Seeking Alpha
Palvella Therapeutics stock price target maintained at $220 by Clear Street - Investing.com Nigeria
Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from Chardan Capital - MarketBeat
Palvella Therapeutics launches awareness campaign for rare lymphatic disease - MSN
Palvella Therapeutics stock price target maintained at $220 by Clear Street By Investing.com - Investing.com India
Palvella Therapeutics Launches Awareness Campaign for Rare Lymphatic Disease - MyChesCo
Palvella receives European patent for rapamycin gel formulation - Investing.com
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin - GlobeNewswire
First Light Asset Management LLC Buys New Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Apis Capital Advisors LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Suvretta Capital Management LLC Boosts Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Shares Down 8.7%Should You Sell? - MarketBeat
Palvella launches disease awareness campaign for rare lymphatic condition - Investing.com Nigeria
Quarterly Earnings: Can Palvella Therapeutics Inc lead its sector in growth2026 Price Swings & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Chipmakers Recap: Can Palvella Therapeutics Inc deliver alphaQuarterly Market Summary & Low Drawdown Investment Ideas - baoquankhu1.vn
Palvella launches disease awareness campaign for rare lymphatic condition By Investing.com - Investing.com South Africa
Palvella Therapeutics stock rating maintained at Buy by Clear Street - Investing.com Nigeria
Palvella Therapeutics Launches "BEYOND mLM" Disease - GlobeNewswire
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Palvella Therapeutics Reports Q1 2025 Financials and Clinical Progress - MSN
Palvella Therapeutics Names Ashley Kline Chief Commercial Officer - MSN
Published on: 2026-03-07 20:09:49 - baoquankhu1.vn
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
Blue Owl Capital Holdings LP Reduces Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
PVLA Stock Soars On Strong Phase 3 Results For Rare Vascular Disorder Treatment - Stocktwits
Aug Closing: Is Palvella Therapeutics Inc stock trending bullishJuly 2025 Final Week & Real-Time Chart Pattern Alerts - baoquankhu1.vn
Royce & Associates LP Decreases Stock Holdings in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Update - MarketBeat
Palvella Reports Phase 3 Success for QTORIN in Rare Skin Disorder - MyChesCo
Palvella therapeutics (PVLA) director buys $500k in stock By Investing.com - Investing.com Australia
Palvella Therapeutics raises $230M in upsized stock offering By Investing.com - Investing.com Canada
Palvella Therapeutics raises $230M in upsized stock offering - Investing.com Australia
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares - Investing.com UK
Heron Elaine J, Palvella therapeutics director, buys $300,000 in shares By Investing.com - Investing.com Canada
Palvella therapeutics (PVLA) director buys $500k in stock - Investing.com South Africa
Palvella Therapeutics (NASDAQ:PVLA) Director Elaine Heron Purchases 2,400 Shares - MarketBeat
Insider Buying: Palvella Therapeutics (NASDAQ:PVLA) Director Acquires 4,000 Shares of Stock - MarketBeat
Palvella Therapeutics Insider Bought Shares Worth $300,000, According to a Recent SEC Filing - marketscreener.com
Assessing Palvella Therapeutics (PVLA) Valuation After Strong Recent Returns And A High P/B Multiple - Yahoo Finance
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - GlobeNewswire
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
Is Palvella Therapeutics (PVLA) Still Attractive After A 7x One-Year Surge In Price? - simplywall.st
PVLA PE Ratio & Valuation, Is PVLA Overvalued - Intellectia AI
Palvella Therapeutics Announces Underwritten Common Stock Offering - The Globe and Mail
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade - Defense World
1.20%
0.06%
자본화:
|
볼륨(24시간):